Serological thresholds of risk reduction for infant group B streptococcus disease
Cantrell, L.; Karampatsas, K.; Andrews, N.; Beach, S.; Bentley, E.; Berardi, A.; Bijlsma, M. W.; Cagil Kocana, C.; Daniel, O.; French, N.; Hall, T.; Izu, A.; Khalil, A.; Kwatra, G.; Kyohere, M.; Madhi, S. A.; Mboizi, R.; Miselli, F.; Nielsen, M.; Thorn, N.; van de Beek, D.; Walker, K.; Heath, P. T.; Le Doare, K.; Voysey, M.; PREPARE WP3 Study Group,
Show abstract
Vaccines to prevent infant group B streptococcus (GBS) disease are advancing, with licensure likely based on safety and immunologic endpoints rather than clinical efficacy data. This approach requires robust, generalisable serological thresholds of risk reduction (SToRRs). We combined data from six case-control studies in Europe and Africa to define SToRRs for early-onset (EOD) and late-onset (LOD) GBS disease. Across diverse epidemiological and healthcare settings, anti-capsular polysaccharide IgG concentrations were consistently higher in infants who remained disease free than in those who developed disease. Higher antibody concentrations were required to reduce the risk of EOD than LOD, and higher concentrations were required for serotype Ia than for serotype III. This study provides a quantitative framework to support correlates-based evaluation and potential licensure of maternal GBS vaccines.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.